Results 31 to 40 of about 989 (143)

Bilastine: new insight into antihistamine treatment [PDF]

, 2015
Bilastine is a new second generation H1-antihistamine recently approved for the symptomatic treatment of allergic rhinitis (AR) and chronic urticaria (CU).
RIDOLO, Erminia, Giorgio Walter Canonica, Marcello Montagni, Erminia Ridolo, Canonica, Giorgio Walter, Laura Bonzano, Incorvaia, Cristoforo, Montagni, Marcello, Bonzano, Laura, Cristoforo Incorvaia, CANONICA, GIORGIO   +10 more
core   +1 more source

Delayed urticaria during treatment with anti-CGRP monoclonal antibodies in migraine. [PDF]

Headache
Abstract Objective To characterize clinical presentation and management of urticaria associated with calcitonin gene‐related peptide (CGRP) ‐targeting monoclonal antibodies (mAbs) for migraine prophylaxis. Background CGRP‐targeting mAbs are effective in migraine prophylaxis, but have been associated with hypersensitivity reactions, including urticaria.
Berger CT, Villena FB, Vogt SB, Heydrich L, Hartmann K, Papadopoulou A.   +5 more
europepmc   +2 more sources

The Efficacy and Safety of Bilastine in the Treatment of Perennial Allergic Rhinitis in Patients with Moderate and Severe Forms of the Disease. Comparison of bilastine 20 mg with desloratadine 5 mg Сергей

Медицинский совет, 2019
Background: Bilastine is a new non-sedating H1 antihistamine approved for the symptomatic treatment of allergic rhinoconjunctivitis (ARC) and urticaria in adults and children over 12 years of age.
S. Ryazantsev, I. Gogunska, I. Lymar, L. Romanyuk, B. Bil, S. Pukhlik, V. Pravdyva, V. Lapshyn, V. Koshlia   +8 more
doaj   +1 more source

Safety profile of bilastine : 2nd generation H1-antihistamines

, 2012
Bilastine is a new H1 antagonist with no sedative side effects, no cardiotoxic effects, and no hepatic metabolism. In addition, bilastine has proved to be effective for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria ...
F. Scaglione
core   +2 more sources

Entrapped Transient Chloroform Solvates of Bilastine

Crystals, 2021
The knowledge about the solid forms landscape of Bilastine (BL) has been extended. The crystal structures of two anhydrous forms have been determined, and the relative thermodynamic stability among the three known anhydrous polymorphs has been ...
Cristina Puigjaner, Anna Portell, Arturo Blasco, Mercè Font-Bardia, Oriol Vallcorba   +4 more
doaj   +1 more source

Real-life experience of efficacy and safety of bilastine in the refractory cases of chronic spontaneous urticaria and its effect on the quality of life of patients

Indian Journal of Dermatology, 2021
Introduction: Second-generation H1-antihistamines (SGAHs) are the mainstay of treatment of chronic spontaneous urticaria (CSU). Bilastine, newer non-sedating SGAHs, was recently introduced in India after the approval of the Drugs Controller General of ...
Abhishek De, Kiran Godse, Dhiraj Dhoot, Aarti Sarda   +3 more
doaj   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira   +2 more
wiley   +1 more source

Management of chronic urticaria: Current status and future prospect

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Chronic urticaria is driven by mast cell activation through autoimmune, inflammatory, and neuroimmune pathways. A structured approach combining diagnosis, patient‐reported outcomes, stepwise therapy, treatment optimization, monitoring and emerging targeted agents may improve disease control and enable more personalized management.
Andaç Salman, Mona Al‐Ahmad, Maryam Al‐Nesf, Chia‐Yu Chu, Luis Felipe Ensina, Ana M. Gimenez‐Arnau, Margarida Gonçalo, Clive Grattan, Michihiro Hide, Pavel Kolkhir, Martin Metz, Iman Nasr, Romi Saini, Simon Francis Thomsen, Torsten Zuberbier, Emek Kocaturk   +15 more
wiley   +1 more source

Bilastine: An environmental risk assessment

, 2015
Publisher Copyright: © 2015 Informa Healthcare USA, Inc.Context: Bilastine is a new oral selective, non-sedating histamine H1 antagonist for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria.
Ledo, Francisco, Lucero, María Luisa, Peither, Armin   +2 more
core   +1 more source

Evaluation of efficacy and safety of bilastine 20 mg tablets in adult patients with allergic rhinitis [PDF]

, 2022
Background: Bilastine is a nonsedating, H1-antihistamine used for symptomatic treatment of allergic rhinitis; However, data on its efficacy and safety in Indian patients with allergic rhinitis are lacking.Methods: In this multicenter, single-arm ...
Bhargava, Samir, Ramappa, Chidananda, Padmanabhan, Karthikeyan   +2 more
core   +1 more source